Clinical trials: Hyperphosphatemia
End Stage Renal Disease, Hyperphosphatemia
Phosphate Microvascular Study
Elevated phosphate concentrations in the blood have been associated with multiple negative health outcomes in patients with chronic kidney disease as well as in the general population.
- Trial name
- NCT03594539
- Testing
- Withholding standard phosphate binder
- Volunteers
- 20 people
- Sponsor
- Veterans Medical Research Foundation
End-Stage Kidney Disease, Hyperphosphatemia
Explore the Effectors of The Transtheoretical Model on Nutritional Education in Patients on Hemodialysis
The purpose of this study is to assess the improvement degree of nutritional care program on the nutritional status and eating habits of hemodialysis patients
- Trial name
- NCT05897502
- Testing
- multimedia education
- Where
- Taiwan
- Volunteers
- 43 people
- Sponsor
- Liu, Liu-Yin
Kidney Failure, Chronic
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease…
- Trial name
- LEAP (NCT00853242)
- Testing
- Genz-644470, Sevelamer carbonate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 349 people
- Sponsor
- Genzyme, a Sanofi Company
End-stage Renal Disease
Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients
The goal of this clinical trial is to learn if Niacin has an effect on lipoprotein (a) concentration and hyperphosphatemia, which represent strong risk factors for cardiovascular diseases, in End-stage renal disease (ESRD)…
- Trial name
- NCT06406140
- Testing
- Niacin tablets 500 mg
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
Hyperphosphatemia Patients on Hemodialysis
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
- Trial name
- NCT07285304
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia
Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia
With calcium carbonate as the positive control drug, to observe the effectiveness and safety of nicotinic acid in hemodialysis patients with hyperphosphatemia
- Trial name
- NAHPH (NCT02836184)
- Testing
- Nicotinic Acids, Calcium Carbonate
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiujiang No.1 People's Hospital
Hyperphosphatemia
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in…
- Trial name
- NCT04766398
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 169 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia Related to Chronic Kidney Disease
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
- Trial name
- NCT04523727
- Testing
- ferric citrate
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Keryx Biopharmaceuticals
Renal Insufficiency, Chronic, Dialysis
Egg White for Phosphorus Control in Haemodialysis Patients
To evaluate the effect on phosphatemia in hemodialysis patients of replacing the meat or fish included in two meals a week with an amount of egg white containing the same quantity of proteins.
- Conditions
- Renal Insufficiency, Chronic, Dialysis, Hyperphosphatemia
- Trial name
- UAUDIPE (NCT03236701)
- Testing
- Egg White replacement
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Chronic Kidney Disease, End Stage Renal Disease
Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia
Patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD) undergoing renal replacement therapies show elevated serum phosphate levels which predispose them to cardiovascular calcifications and high…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Hyperphosphatemia, Renal Osteodystrophy
- Trial name
- NCT00374712
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hyperphosphatemia, End-stage Renal Disease
Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients
Hyperphosphatemia is an independent risk factor for mortality among dialysis patients. And most phosphate in human is derived from the food.
- Trial name
- NCT02755961
- Testing
- Dietary education, Education on phosphate binder use
- Volunteers
- 70 people
- Sponsor
- Ajou University School of Medicine
Hyperphosphatemia, Chronic Kidney Disease
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced.
- Trial name
- OsvaRenNEW (NCT02027662)
- Testing
- Osvaren Granules, Osvaren film-coated tablets
- Where
- 11 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hyperphosphatemia in Chronic Kidney Disease
Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate
Patients with end-stage renal disease (ESRD) commonly have high concentrations of phosphorous, a mineral, in the blood (hyperphosphatemia). This is a result of their inability to excrete phosphorous by the kidneys.
- Trial name
- NCT00458289
- Testing
- Lanthanum carbonate (chewed vs. crushed)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis
Long-term Extension Study of MCI-196
The Primary Objectives of this study are to assess the long-term efficacy of treatment with colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of treatment with colestilan (MCI-196) (including…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01814917
- Testing
- colestilan, CBPB
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Failure
An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate
Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at the safety of fermagate over longer periods of time.
- Trial name
- ALCON (NCT00358722)
- Testing
- Fermagate
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Ineos Healthcare Limited
Chronic Kidney Disease(CKD), Hyperphosphatemia
Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease
As Chronic Kidney Disease (CKD) progresses normophosphatemia is maintained by increasing the per nephron urinary phosphorus excretion.
- Conditions
- Chronic Kidney Disease(CKD), Hyperphosphatemia, Blood Pressure
- Trial name
- CKD (NCT04579315)
- Testing
- Intervention group; NNRD group
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Bo Feldt-Rasmussen
Kidney Failure, Chronic, End-Stage Renal Disease
Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
The purpose of this study is to perform a randomized, controlled clinical trial to investigate if the phosphate binder sevelamer can improve insulin resistance and glucose handling in patients receiving maintenance hemodialysis.
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Insulin Resistance, Hyperphosphatemia
- Trial name
- SIR (NCT00837655)
- Testing
- Sevelamer, Calcium carbonate
- Where
- 2 sites in Sweden
- Sponsor
- Karolinska Institutet
Hypophosphatemia, Familial, Rickets
Hypophosphatemic Rickets in Norway
The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence.
- Conditions
- Hypophosphatemia, Familial, Rickets, Hyperphosphatemia
- Trial name
- NCT01057186
- Testing
- Alfacalcidol; phosphate., Sevelamer
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
End Stage Renal Disease, Chronic Kidney Disease
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
The primary objectives of this study are the following: 1. To demonstrate that AMG 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with…
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease, Hyperphosphatemic, Kidney Disease
- Trial name
- NCT00530114
- Testing
- AMG 223
- Volunteers
- 167 people
- Sponsor
- Amgen